Eric de La Fortelle, PH.D.Venture Partner - Seventure

    Eric is a Venture Partner with Seventure Partners, a Paris-based venture capital investor investing broadly in life sciences (Rx, Dx, medical device) with a specific focus on the human microbiome. Seventure has raised the first fund worldwide dedicated to the microbiome, called Health for Life, in Dec 2015. Eric sits on the Board of directors of Mint Solutions BV, Maat Pharma SA, TargEDys SA, Anaeropharma Ltd. (observer), BiomX Ltd., DayTwo Ltd. (Observer), A-Mansia SA, NeurIMM SA and Siolta Therapeutics, Inc (observer). as a representative for Seventure, and of Sensorion SA as an independent director.

    Formerly, Eric was CEO of Delenex Therapeutics, a Zurich-based biotechnology company discovering and developing antibodies for topical application to the skin. Prior to that he led Roche’s global function of External Research and Technologies. In this role, he had a dual mandate of BD&L (finding partners, negotiating contracts, managing alliances), leading to more than 200 deals being signed, and prospective (future scenarios to 2020 and R&D strategy recommendations).

    Eric is a scientist by training, with contributions in the field of protein structure determination by X-ray crystallography. He was trained as an engineer and physicist at Ecole Centrale de Paris, holds a Ph.D. in Biophysics from Paris XI University, a post-graduate diploma in biomedicine from IFSBM (Institut Gustave-Roussy), and an MBA (honors) from INSEAD.